|
|
Article: Five mutations to watch for: VTE risk and thrombogenic mutations in pregnancy.(Obstetrics)
- Article from:
- OB GYN News
- Article date:
- September 1, 2004
- Author:
CopyrightCOPYRIGHT 2004 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LAS VEGAS -- There are six key thrombogenic mutations to be concerned about in pregnant patients, Dr. Charles Lock-wood said at the Fifth World Congress on Controversies in Obstetrics, Gynecology, and Infertility.
These include:
* Factor V Leiden mutation. About 80% of women with activated C-reactive protein resistance have this mutation. Both men and women with factor V Leiden mutation face a 30% lifetime risk of venous thromboembolism (VTE), and the prevalence in Europeans ranges from 5% to 15%. The prevalence of the mutation in the United States is about 5%, said Dr. Lockwood, who chairs the department of obstetrics, gynecology, and reproductive ...